FeesSafety
Pluang+

Bitcoin mining difficulty drops 5%, easing pressure amid falling hashrate and rising hashprice.

Market News
12 Jul 2026, 21:30 WIB
Bitcoin
View Source
Neutral
Bitcoin mining difficulty drops 5%, easing pressure amid falling hashrate and rising hashprice.

On July 11, 2026, Bitcoin's mining difficulty decreased by 5% to 127.17 trillion, marking the 14th adjustment of the year and moving closer to its yearly low. This drop was driven by a 7.9% decline in hashrate over ten days, slowing block production and prompting the difficulty cut. Meanwhile, the hashprice—the expected miner revenue per petahash—rose 12.5% to $31.1 but remains 37.2% below its peak from October 2025. The pattern of fluctuating difficulty, hashrate, and hashprice throughout 2026 indicates miners are adjusting to tighter margins, with computing power stabilizing in a lower range. This suggests a mining sector balancing between recovery and ongoing challenges rather than a sustained downturn.

More News

New data shows nipocalimab improves mouth dryness in Sjögren's disease, with Phase 3 trials underway.

New data shows nipocalimab improves mouth dryness in Sjögren's disease, with Phase 3 trials underway.

Johnson & Johnson announced new patient data from the Phase 2 DAHLIAS study showing nipocalimab significantly improves mouth dryness, the most impactful symptom for Sjögren's disease patients. The drug also increased saliva production by 50% in more ...

Company Fundamentals
Bullish
5 hours ago
ICOTYDE shows strong Phase 3 results for psoriatic arthritis with 58% ACR20 response at 16 weeks

ICOTYDE shows strong Phase 3 results for psoriatic arthritis with 58% ACR20 response at 16 weeks

Johnson & Johnson announced positive Phase 3 trial results for ICOTYDE (icotrokinra), an oral peptide targeting IL-23R, in treating biologic-naïve adults with active psoriatic arthritis. At 16 weeks, 58% of patients achieved ACR20 response versus 41%...

Company Fundamentals
Bullish
5 hours ago
Phase 3 ALKIVIA study shows efgartigimod improves autoimmune myositis symptoms, meeting key endpoints.

Phase 3 ALKIVIA study shows efgartigimod improves autoimmune myositis symptoms, meeting key endpoints.

The Phase 3 ALKIVIA study by argenx demonstrated that efgartigimod significantly improved symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). The study met its primary and key...

Company Fundamentals
Bullish
5 hours ago
Uber lags in robotaxi race with slow growth and weak profits, warns of value trap at current stock price.

Uber lags in robotaxi race with slow growth and weak profits, warns of value trap at current stock price.

Uber Technologies is falling behind competitors Waymo and Tesla in the U.S. robotaxi market, projecting only 2,000 robotaxis by 2027 compared to Waymo's 20,000 and Tesla's plans for millions. The company's revenue growth is slowing, with Q3 growth un...

Market News
Bearish
5 hours ago
Bitcoin mining power surpasses one zettahash as competition strengthens again

Bitcoin mining power surpasses one zettahash as competition strengthens again

Bitcoin's total mining hashrate has rebounded above one zettahash over the past week, signaling renewed strength in the network's mining competition. This recovery suggests that recent exits by some mining companies do not indicate an overall decline...

Market News
Neutral
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App